Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the p110δ/γ Crystal Structure

Wen-Qing	      Jia; Xiao-Yan	      Feng; Ya-Ya	      Liu; Zhen-Zhen	      Han; Zhi      Jing; Wei-Ren	      Xu; Xian-Chao	      Cheng

doi:10.2174/1570180816666190730163431

Abstract

Background: Phosphoinositide-3 kinases (PI3Ks) are key signaling molecules that affect a diverse array of biological processes in cells, including proliferation, differentiation, survival, and metabolism. The abnormal activity of PI3K signals is closely related to the occurrence of many diseases, which has become a very promising drug target, especially for the treatment of cancer. PI3Kδ/γ inhibitors can reduce toxicity concerns for chronic indications such as asthma and rheumatoid arthritis compared with pan PI3Ks inhibitors.

Methods: With the aim of finding more effective PI3Kδ/γ dual inhibitors, virtual screening, ADMET prediction Molecular Dynamics (MD) simulations and MM-GBSA were executed based on the known p110δ/γ crystal structure. Compound ZINC28564067 with high docking score and low toxicity was obtained.

Results: By MD simulations and MM-GBSA, we could observe that ZINC28564067 had more favorable conformation binding to the PI3Kδ/γ than the original ligands.

Conclusion: The results provided a rapid approach for the discovery of novel PI3Kδ/γ dual inhibitors which might be a potential anti-tumor lead compound.

Keywords: Anti-tumor lead compound, ADMET, molecular dynamics, PI3Kδ/γ dual inhibitors, virtual screening, MM-GBSA, phosphoinositide-3 kinases.

« Previous Next »

Graphical Abstract

[1] 
Liu, X.; Jing, Z.; Jia, W.Q.; Wang, S.Q.; Ma, 
Y.; Xu, W.R.; Liu, J.W.; Cheng, X.C. Identification of novel PPARα/γ 
dual agonists by virtual screening, ADMET prediction and molecular 
dynamics simulations. J. Biomol. Struct. Dyn.,  2018, 36(11), 2988-3002.
[http://dx.doi.org/10.1080/07391102.2017.1373706] [PMID: 28853334] 
[2] 
Thapa, N.; Choi, S.; Tan, X.; Wise, T.; 
Anderson, R.A. Phosphatidylinositol Phosphate 5-Kinase Iγ and 
Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic 
Growth. J. Biol. Chem.,  2015, 290(30), 18843-18854.
[http://dx.doi.org/10.1074/jbc.M114.596742] [PMID: 26070568] 
[3] 
Liu, Y.; Wan, W.Z.; Li, Y.; Zhou, G.L.; Liu, 
X.G. Recent development of ATP-competitive small molecule 
phosphatidylinostitol-3-kinase inhibitors as anticancer agents. Oncotarget,  2017, 8(4), 7181-7200.
[http://dx.doi.org/10.18632/oncotarget.12742] [PMID: 27769061] 
[4] 
Maira, S-M.; Voliva, C.; Garcia-Echeverria, C.
 Class IA phosphatidylinositol 3-kinase: from their biologic implication
 in human cancers to drug discovery. Expert Opin. Ther. Targets,  2008, 12(2), 223-238.
[http://dx.doi.org/10.1517/14728222.12.2.223] [PMID: 18208370] 
[5] 
Ameriks, M.K.; Venable, J.D. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ. Curr. Top. Med. Chem.,  2009, 9(8), 738-753.
[http://dx.doi.org/10.2174/156802609789044434] [PMID: 19689378] 
[6] 
Rewcastle, G.W.; Gamage, S.A.; Flanagan, J.U.;
 Frederick, R.; Denny, W.A.; Baguley, B.C.; Kestell, P.; Singh, R.; 
Kendall, J.D.; Marshall, E.S.; Lill, C.L.; Lee, W.J.; Kolekar, S.; 
Buchanan, C.M.; Jamieson, S.M.; Shepherd, P.R. Synthesis and biological 
evaluation of novel analogues of the pan class I phosphatidylinositol 
3-kinase (PI3K) inhibitor 
2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole
 (ZSTK474). J. Med. Chem.,  2011, 54(20), 7105-7126.
[http://dx.doi.org/10.1021/jm200688y] [PMID: 21882832] 
[7] 
Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci.,  2008, 99(9), 1734-1740.
[http://dx.doi.org/10.1111/j.1349-7006.2008.00891.x] [PMID: 18616528] 
[8] 
Okkenhaug, K.; Bilancio, A.; Farjot, G.; 
Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S.E.; Salpekar, 
A.; Waterfield, M.D.; Smith, A.J.H.; Vanhaesebroeck, B. Impaired B and T
 cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science,  2002, 297(5583), 1031-1034.
[http://dx.doi.org/10.1126/science.1073560] [PMID: 12130661] 
[9] 
Vanhaesebroeck, B.; Guillermet-Guibert, J.; 
Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific 
PI3K signalling. Nat. Rev. Mol. Cell Biol.,  2010, 11(5), 329-341.
[http://dx.doi.org/10.1038/nrm2882] [PMID: 20379207] 
[10] 
Ferguson, F.M.; Ni, J.; Zhang, T.; Tesar, B.; 
Sim, T.; Kim, N.D.; Deng, X.; Brown, J.R.; Zhao, J.J.; Gray, N.S. 
Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors. ACS Med. Chem. Lett.,  2016, 7(10), 908-912.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00209] [PMID: 27774127] 
[11] 
Flinn, I.W.; O’Brien, S.; Kahl, B.; Patel, M.;
 Oki, Y.; Foss, F.F.; Porcu, P.; Jones, J.; Burger, J.A.; Jain, N.; 
Kelly, V.M.; Allen, K.; Douglas, M.; Sweeney, J.; Kelly, P.; Horwitz, S.
 Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically 
active in advanced hematologic malignancies. Blood,  2018, 131(8), 877-887.
[http://dx.doi.org/10.1182/blood-2017-05-786566] [PMID: 29191916] 
[12] 
Reif, K.; Okkenhaug, K.; Sasaki, T.; 
Penninger, J.M.; Vanhaesebroeck, B.; Cyster, J.G. Cutting edge: 
differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in 
lymphocyte chemotaxis and homing. J. Immunol.,  2004, 173(4), 2236-2240.
[http://dx.doi.org/10.4049/jimmunol.173.4.2236] [PMID: 15294934] 
[13] 
Markham, A. Copanlisib: First Global Approval. Drugs,  2017, 77(18), 2057-2062.
[http://dx.doi.org/10.1007/s40265-017-0838-6] [PMID: 29127587] 
[14] 
Scott, W.J.; Hentemann, M.F.; Rowley, R.B.; 
Bull, C.O.; Jenkins, S.; Bullion, A.M.; Johnson, J.; Redman, A.; 
Robbins, A.H.; Esler, W.; Fracasso, R.P.; Garrison, T.; Hamilton, M.; 
Michels, M.; Wood, J.E.; Wilkie, D.P.; Xiao, H.; Levy, J.; Stasik, E.; 
Liu, N.; Schaefer, M.; Brands, M.; Lefranc, J. Discovery and SAR of 
Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: 
Identification of Copanlisib (BAY 80-6946). ChemMedChem,  2016, 11(14), 1517-1530.
[http://dx.doi.org/10.1002/cmdc.201600148] [PMID: 27310202] 
[15] 
Singh, A.; Thatikonda, T.; Kumar, A.; Wazir, 
P.; v, V.; Nandi, U.; Singh, P.P.; Singh, S.; Gupta, A.P.; Tikoo, M.K.; 
Singh, G.; Vishwakarma, R. Determination of ZSTK474, a novel Pan PI3K 
inhibitor in mouse plasma by LC-MS/MS and its application to 
Pharmacokinetics. J. Pharm. Biomed. Anal.,  2018, 149, 387-393.
[http://dx.doi.org/10.1016/j.jpba.2017.11.031] [PMID: 29175554] 
[16] 
Yaguchi, S.; Fukui, Y.; Koshimizu, I.; 
Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, 
T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase 
inhibitor. J. Natl. Cancer Inst.,  2006, 98(8), 545-556.
[http://dx.doi.org/10.1093/jnci/djj133] [PMID: 16622124] 
[17] 
Gamage, S.A.; Giddens, A.C.; Tsang, K.Y.; 
Flanagan, J.U.; Kendall, J.D.; Lee, W.J.; Baguley, B.C.; Buchanan, C.M.;
 Jamieson, S.M.F.; Shepherd, P.R.; Denny, W.A.; Rewcastle, G.W. 
Synthesis and biological evaluation of sulfonamide analogues of the 
phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorg. Med. Chem.,  2017, 25(20), 5859-5874.
[http://dx.doi.org/10.1016/j.bmc.2017.09.025] [PMID: 28958845] 
[18] 
Patnaik, A.; Appleman, L.J.; Tolcher, A.W.; 
Papadopoulos, K.P.; Beeram, M.; Rasco, D.W.; Weiss, G.J.; Sachdev, J.C.;
 Chadha, M.; Fulk, M.; Ejadi, S.; Mountz, J.M.; Lotze, M.T.; Toledo, 
F.G.; Chu, E.; Jeffers, M.; Peña, C.; Xia, C.; Reif, S.; Genvresse, I.; 
Ramanathan, R.K. First-in-human phase I study of copanlisib (BAY 
80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase 
inhibitor, in patients with advanced solid tumors and non-Hodgkin’s 
lymphomas. Ann. Oncol.,  2016, 27, 1928-1940.
[http://dx.doi.org/10.1093/annonc/mdw282] [PMID: 27672108] 
[19] 
Berndt, A.; Miller, S.; Williams, O.; Le, 
D.D.; Houseman, B.T.; Pacold, J.I.; Gorrec, F.; Hon, W.C.; Liu, Y.; 
Rommel, C.; Gaillard, P.; Rückle, T.; Schwarz, M.K.; Shokat, K.M.; Shaw,
 J.P.; Williams, R.L. The p110 delta structure: mechanisms for 
selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol.,  2010, 6(2), 117-124.
[http://dx.doi.org/10.1038/nchembio.293] [PMID: 20081827] 
[20] 
Miller, M.S.; Mountford, S.J.; Pinson, J-A.; 
Zheng, Z.; Künzli, M.; Patel, V.; Hogg, S.J.; Shortt, J.; Jennings, 
I.G.; Thompson, P.E. Development of single and mixed isoform selectivity
 PI3Kδ inhibitors by targeting Asn836 of PI3Kδ. Bioorg. Med. Chem. Lett.,  2016, 26(19), 4790-4794.
[http://dx.doi.org/10.1016/j.bmcl.2016.08.028] [PMID: 27561716] 
[21] 
Zhang, J.; Liu, X.; Wang, S.Q.; Fu, J.W.; Xu, 
W.R.; Cheng, X.C.; Wang, R.L. Identification of Novel PPARα/γ Dual 
Agonists by Virtual Screening of Specs Database. Comb. Chem. High Throughput Screen.,  2016, 19(8), 644-655.
[http://dx.doi.org/10.2174/1386207319666160615013027] [PMID: 27316369] 
[22] 
Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; 
Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. Glide: a new 
approach for rapid, accurate docking and scoring. 2. Enrichment factors 
in database screening. J. Med. Chem.,  2004, 47(7), 1750-1759.
[http://dx.doi.org/10.1021/jm030644s] [PMID: 15027866] 
[23] 
Thangapandian, S.; John, S.; Lee, Y.; Kim, S.;
 Lee, K.W. Dynamic structure-based pharmacophore model development: a 
new and effective addition in the histone deacetylase 8 (HDAC8) 
inhibitor discovery. Int. J. Mol. Sci.,  2011, 12(12), 9440-9462.
[http://dx.doi.org/10.3390/ijms12129440] [PMID: 22272142] 
[24] 
Sastry, G.M.; Adzhigirey, M.; Day, T.; 
Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters,
 protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des.,  2013, 27(3), 221-234.
[http://dx.doi.org/10.1007/s10822-013-9644-8] [PMID: 23579614] 
[25] 
Hasan, M.A.; Mazumder, M.H.H.; Chowdhury, 
A.S.; Datta, A.; Khan, M.A. Molecular-docking study of malaria drug 
target enzyme transketolase in Plasmodium falciparum 3D7 portends the 
novel approach to its treatment. Source Code Biol. Med.,  2015, 10, 7.
[http://dx.doi.org/10.1186/s13029-015-0037-3] [PMID: 26089981] 
[26] 
Rajamanikandan, S.; Srinivasan, P. 
Pharmacophore modeling and structure-based virtual screening to identify
 potent inhibitors targeting LuxP of Vibrio harveyi. J. Recept. Signal Transduct. Res.,  2016, 36(6), 617-632.
[http://dx.doi.org/10.3109/10799893.2016.1155063] [PMID: 27049472] 
[27] 
Wang, X.J.; Zhang, J.; Wang, S.Q.; Xu, W.R.; 
Cheng, X.C.; Wang, R.L. Identification of novel multitargeted PPARα/γ/δ 
pan agonists by core hopping of rosiglitazone. Drug Des. Devel. Ther.,  2014, 8, 2255-2262.
[PMID: 25422585] 
[28] 
Ahmad, S.; Khan, M.F.; Parvez, S.; Akhtar, M.;
 Raisuddin, S. Molecular docking reveals the potential of phthalate 
esters to inhibit the enzymes of the glucocorticoid biosynthesis 
pathway. J. Appl. Toxicol.,  2017, 37(3), 265-277.
[http://dx.doi.org/10.1002/jat.3355] [PMID: 27427409] 
[29] 
Allen, B.K.; Mehta, S.; Ember, S.W.J.; Zhu, 
J-Y.; Schönbrunn, E.; Ayad, N.G.; Schürer, S.C. Identification of a 
Novel Class of BRD4 Inhibitors by Computational Screening and Binding 
Simulations. ACS Omega,  2017, 2(8), 4760-4771.
[http://dx.doi.org/10.1021/acsomega.7b00553] [PMID: 28884163] 
[30] 
Umamaheswari, A.; Pradhan, D.; Hemanthkumar, 
M. Identification of potential Leptospira phosphoheptose isomerase 
inhibitors through virtual high-throughput screening. Genomics Proteomics Bioinformatics,  2010, 8(4), 246-255.
[http://dx.doi.org/10.1016/S1672-0229(10)60026-5] [PMID: 21382593] 
[31] 
Jia, W.Q.; Jing, Z.; Liu, X.; Feng, X.Y.; Liu,
 Y.Y.; Wang, S.Q.; Xu, W.R.; Liu, J.W.; Cheng, X.C. Virtual 
identification of novel PPARα/γ dual agonists by scaffold hopping of 
saroglitazar. J. Biomol. Struct. Dyn.,  2018, 36(13), 3496-3512.
[http://dx.doi.org/10.1080/07391102.2017.1392363] [PMID: 29081262] 
[32] 
Puratchikody, A.; Sriram, D.; Umamaheswari, 
A.; Irfan, N. 3-D structural interactions and quantitative structural 
toxicity studies of tyrosine derivatives intended for safe potent 
inflammation treatment. Chem. Cent. J.,  2016, 10, 24.
[http://dx.doi.org/10.1186/s13065-016-0169-9] [PMID: 27141229] 
[33] 
Ahmad, A.; Ahmad, A.; Sudhakar, R.; Varshney, 
H.; Subbarao, N.; Ansari, S.; Rauf, A.; Khan, A.U. Designing, synthesis,
 and antimicrobial action of oxazoline and thiazoline derivatives of 
fatty acid esters. J. Biomol. Struct. Dyn.,  2017, 35(15), 3412-3431.
[http://dx.doi.org/10.1080/07391102.2016.1255260] [PMID: 27801287] 
[34] 
Yadava, U.; Gupta, H.; Roychoudhury, M. 
Stabilization of microtubules by taxane diterpenoids: insight from 
docking and MD simulations. J. Biol. Phys.,  2015, 41(2), 117-133.
[http://dx.doi.org/10.1007/s10867-014-9369-5] [PMID: 25542396] 
[35] 
Katari, S.K.; Natarajan, P.; Swargam, S.; 
Kanipakam, H.; Pasala, C.; Umamaheswari, A. Inhibitor design against 
JNK1 through e-pharmacophore modeling docking and molecular dynamics 
simulations. J. Recept. Signal Transduct. Res.,  2016, 36(6), 558-571.
[http://dx.doi.org/10.3109/10799893.2016.1141955] [PMID: 26906522] 
[36] 
Kallubai, M.; Amineni, U.; Mallavarapu, M.; 
Kadiyala, V. In Silico Approach to Support that p-Nitrophenol 
Monooxygenase from Arthrobacter sp. Strain JS443 Catalyzes the Initial 
Two Sequential Monooxygenations. Interdiscip. Sci.,  2015, 7(2), 157-167.
[http://dx.doi.org/10.1007/s12539-015-0018-x] [PMID: 26272475] 
[37] 
Huang, Y.; Chen, W.; Wallace, J.A.; Shen, J. 
All-Atom Continuous Constant pH Molecular Dynamics With Particle Mesh 
Ewald and Titratable Water. J. Chem. Theory Comput.,  2016, 12(11), 5411-5421.
[http://dx.doi.org/10.1021/acs.jctc.6b00552] [PMID: 27709966] 
[38] 
Hayes, J.M.; Skamnaki, V.T.; Archontis, G.; 
Lamprakis, C.; Sarrou, J.; Bischler, N.; Skaltsounis, A.L.; Zographos, 
S.E.; Oikonomakos, N.G. Kinetics, in silico docking, molecular dynamics,
 and MM-GBSA binding studies on prototype indirubins, KT5720, and 
staurosporine as phosphorylase kinase ATP-binding site inhibitors: the 
role of water molecules examined. Proteins,  2011, 79(3), 703-719.
[http://dx.doi.org/10.1002/prot.22890] [PMID: 21287607] 
[39] 
Pradhan, D.; Priyadarshini, V.; Munikumar, M.;
 Swargam, S.; Umamaheswari, A.; Bitla, A. Para-(benzoyl)-phenylalanine 
as a potential inhibitor against LpxC of Leptospira spp.: homology 
modeling, docking, and molecular dynamics study. J. Biomol. Struct. Dyn.,  2014, 32(2), 171-185.
[http://dx.doi.org/10.1080/07391102.2012.758056] [PMID: 23383626] 
[40] 
Jatana, N.; Jangid, S.; Khare, G.; Tyagi, 
A.K.; Latha, N. Molecular modeling studies of Fatty acyl-CoA synthetase 
(FadD13) from Mycobacterium tuberculosis--a potential target for the 
development of antitubercular drugs. J. Mol. Model.,  2011, 17(2), 301-313.
[http://dx.doi.org/10.1007/s00894-010-0727-3] [PMID: 20454815] 
[41] 
Vilar, S.; Karpiak, J.; Berk, B.; Costanzi, S.
 In silico analysis of the binding of agonists and blockers to the 
β2-adrenergic receptor. J. Mol. Graph. Model.,  2011, 29(6), 809-817.
[http://dx.doi.org/10.1016/j.jmgm.2011.01.005] [PMID: 21334234] 
[42] 
Knight, Z.A.; Feldman, M.E.; Balla, A.; Balla, T.; Shokat, K.M. A membrane capture assay for lipid kinase activity. Nat. Protoc.,  2007, 2(10), 2459-2466.
[http://dx.doi.org/10.1038/nprot.2007.361] [PMID: 17947987] 
[43] 
Vangapandu, H.V.; Jain, N.; Gandhi, V. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin. Investig. Drugs,  2017, 26(5), 625-632.
[http://dx.doi.org/10.1080/13543784.2017.1312338] [PMID: 28388280] 
[44] 
Hossain, M.U.; Khan, M.A.; Rakib-Uz-Zaman, 
S.M.; Ali, M.T.; Islam, M.S.; Keya, C.A.; Salimullah, M. Treating 
Diabetes Mellitus: Pharmacophore Based Designing of Potential Drugs from
 Gymnema sylvestre against Insulin Receptor Protein. BioMed Res. Int.,  2016, 20163187647
[http://dx.doi.org/10.1155/2016/3187647] [PMID: 27034931] 
[45] 
Gholami, S.; Bordbar, A.K.; Lohrasebi, A. 
Identifying binding modes of two synthetic derivatives of adrenalin to 
the α2C-adrenoceptor by using molecular modeling; insights into the 
α2C-adrenoceptor activation. Biophys. Chem.,  2017, 223, 17-24.
[http://dx.doi.org/10.1016/j.bpc.2017.01.005] [PMID: 28187351] 
[46] 
Yokoyama, M.; Fujisaki, S.; Shirakura, M.; 
Watanabe, S.; Odagiri, T.; Ito, K.; Sato, H. Molecular Dynamics 
Simulation of the Influenza A(H3N2) Hemagglutinin Trimer Reveals the 
Structural Basis for Adaptive Evolution of the Recent Epidemic Clade 
3C.2a. Front. Microbiol.,  2017, 8, 584.
[http://dx.doi.org/10.3389/fmicb.2017.00584] [PMID: 28443077] 
[47] 
Sharma, V.K.; Abbat, S.; Bharatam, P.V. 
Pharmacoinformatic Study on the Selective Inhibition of the Protozoan 
Dihydrofolate Reductase Enzymes. Mol. Inform.,  2017, 36(11)1600156
[http://dx.doi.org/10.1002/minf.201600156] [PMID: 28605138] 
[48] 
Cruz, J.N.; Costa, J.F.S.; Khayat, A.S.; Kuca,
 K.; Barros, C.A.L.; Neto, A.M.J.C. Molecular dynamics simulation and 
binding free energy studies of novel leads belonging to the benzofuran 
class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13. J. Biomol. Struct. Dyn.,  2019, 37(6), 1616-1627.
[http://dx.doi.org/10.1080/07391102.2018.1462734] [PMID: 29633908] 

Rights & Permissions Print Cite

Article Metrics

17

1

Explore Articles

Open Access

Open Access Articles

DOI https://dx.doi.org/10.2174/1570180816666190730163431	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

Letters in Drug Design & Discovery

Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the p110δ/γ Crystal Structure

Abstract Play Pause

Graphical Abstract

Related Articles

Abstract